Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups

AIDS

Volumn 27, Issue 8, 2013, Pages 1239-1244

  Braibant, Martine ^a   Gong, Eun Yeung ^a,e   Plantier, Jean Christophe ^c   Moreau, Thierry ^a   Alessandri, Elodie ^c   Simon, François ^d   Barin, Francis ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b CHU BRETONNEAU   (France)

^c UNIVERSITÉ DE ROUEN   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Cross group neutralization; HIV 1; PG9 PG16 epitopes

Indexed keywords

EPITOPE; NEUTRALIZING ANTIBODY;

ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MODELS, THEORETICAL; NEUTRALIZATION TESTS;

EID: 84879115266     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835ecb42     Document Type: Article

References (42)

1. Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011; 473:463-469.
2. Korber B, Gnanakaran S. AIDS/HIV. Converging on an HIV vaccine. Science 2011; 333:1589-1590.
3. Mascola JR, Montefiori DC The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28:413-444.
4. Walker LM, Burton DR Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010; 22:358-366.
5. Braibant M, Brunet S, Costagliola D., Rouzioux C, Agut H, Katinger H., et al. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term nonprogressors: prevalence and association with neutralizing activity. AIDS 2006; 20:1923-1930.
6. Simek MD, Rida W, Priddy F.H., Pung P., Carrow E, Laufer DS, et al Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009; 83:7337-7348.
7. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J., Xu W, Ayehunie S, et al Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-206.
8. Balazs AB, Chen J, Hong C.M., Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2011; 481:81-84.
9. Burton DR, Hessell AJ, Keele B.F., Klasse PJ, Ketas TA, Moldt B, et al Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011; 108:11181-11186.
10. Ferrantelli F, Rasmussen RA, Buckley K.A., Li PL, Wang T, Montefiori DC, et al Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004; 189:2167-2173.
11. Hessell AJ, Poignard P, Hunter M., Hangartner L, Tehrani DM, Bleeker W.K., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-954.
12. Hessell AJ, Rakasz EG, Poignard P, Hangartner L., Landucci G, Forthal DN, et al Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5:e1000433.
13. Corti D, Langedijk JP, Hinz A, Seaman M.S., Vanzetta F., Fernandez-Rodriguez BM, et al Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010; 5:e8805.
14. Walker LM, Huber M, Doores K.J., Falkowska E., Pejchal R, Julien JP, et al Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-470.
15. Walker LM, Phogat SK, Chan-Hui PY, Wagner D., Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.
16. Wu X, Yang ZY, Li Y, Hogerkorp C.M., Schief WR, Seaman MS, et al Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856-861.
17. Binley JM, Ban YE, Crooks E.T., Eggink D., Osawa K, Schief WR, Sanders RW Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 2010; 84:5637-5655.
18. Li Y, Migueles SA, Welcher B, Svehla K., Phogat A, Louder MK, et al Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13:1032-1034.
19. Li Y, Svehla K, Louder M.K., Wycuff D., Phogat S, Tang M, et al Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009; 83:1045-1059.
20. Walker LM, Simek MD, Priddy F, Gach J.S., Wagner D., Zwick MB, et al A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010; 6:e1001028.
21. Gurtler LG, Hauser PH, Eberle J, von Brunn A, Knapp S, Zekeng L., et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994; 68:1581-1585.
22. Loussert-Ajaka I., Chaix ML, Korber B, Letourneur F., Gomas E, Allen E, et al Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France. J Virol 1995; 69:5640-5649.
23. Plantier JC, Leoz M, Dickerson J.E., De Oliveira F, Cordonnier F, Lemee V., et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009; 15:871-872.
24. Simon F, Mauclere P, Roques P., Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S., et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998; 4:1032-1037.
25. Vanden Haesevelde M., Decourt JL, De Leys RJ, Vanderborght B, van der Groen G, van Heuverswijn H, Saman E. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol 1994; 68:1586-1596.
26. Keele BF, Van Heuverswyn F, Li Y, Bailes E., Takehisa J, Santiago ML, et al. Chimpanzee reservoirs of pandemic and nonpan-demic HIV-1. Science 2006; 313:523-526.
27. Van Heuverswyn F., Li Y, Neel C., Bailes E, Keele BF, Liu W, et al Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006; 444:164.
28. Vessiere A, Rousset D, Kfutwah A., Leoz M, Depatureaux A, Simon F., Plantier JC. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. J Acquir Immune Defic Syndr 2010; 53:107-110.
29. Barin F, Cazein F, Lot F., Pillonel J, Brunet S, Thierry D., et al. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006. AIDS 2007; 21:2351-2353.
30. Roques P, Robertson DL, Souquiere S, Apetrei C., Nerrienet E, Barre-Sinoussi F, et al Phylogenetic characteristics of three new HIV-1N strains and implications for the origin of group N. AIDS 2004; 18:1371-1381.
31. Delaugerre C, De Oliveira F, Lascoux-Combe C, Plantier J.C., Simon F. HIV-1 group N: travelling beyond Cameroon. Lancet 2011; 378:1894.
32. Vallari A, Bodelle P, Ngansop C., Makamche F, Ndembi N, Mbanya D., et al. Four new HIV-1 group N isolates from Cameroon: Prevalence continues to be low. AIDS Res Hum Retroviruses 2010; 26:109-115.
33. Yamaguchi J, McArthur CP, Vallari A, Coffey R., Bodelle P, Beyeme M, et al HIV-1 Group N: evidence of ongoing transmission in Cameroon. AIDS Res Hum Retroviruses 2006; 22:453-457.
34. Beirnaert E, Nyambi P, Willems B., Heyndrickx L, Colebunders R, Janssens W., van der Groen G. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol 2000; 62:14-24.
35. Ferrantelli F, Kitabwalla M, Rasmussen R.A., Cao C., Chou TC, Katinger H, et al Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies: implications for acquired immunodeficiency syndrome vaccine. J Infect Dis 2004; 189:71-74.
36. Nyambi PN, Nkengasong J, Peeters M., Simon F, Eberle J, Janssens W., et al. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. J Infect Dis 1995; 172:1228-1237.
37. Barin F, Brunet S, Brand D., Moog C, Peyre R, Damond F., et al. Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 core-ceptors. J Infect Dis 2004; 189:322-327.
38. Depatureaux A, Leoz M, De Oliveira F, Gueudin M, Damond F., Descamps D, et al. [Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data]. Med Mal Infect 2010; 40:669-676.
39. Braibant M, Xie J, Samri A., Agut H, Autran B, Barin F. Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain. Virology 2010; 405:81-92.
40. McLellan JS, Pancera M, Carrico C., Gorman J, Julien JP, Khayat R, et al Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011; 480:336-343.
41. Doria-Rose N.A., Georgiev I, O'Dell S, Chuang GY, Staupe R.P., McLellan JS, et al. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol 2012; 86:8319-8323.
42. Moore PL, Gray ES, Sheward D, Madiga M., Ranchobe N, Lai Z, et al Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 2011; 85:3128-3141.